AtaiBeckley Inc. announced peer-reviewed Phase 2a results for BPL-003 (mebufotenin benzoate nasal spray) in treatment-resistant depression, showing a mean MADRS score reduction of 12.6 points by Day 2 that was sustained over 12 weeks. The drug demonstrated a 54.5% response rate and 63.6% remission rate with good tolerability. The Phase 3 program remains on track for initiation in Q2 2026 following a successful FDA End-of-Phase 2 meeting.
AtaiBeckley Inc. Common Stock (ATAI)
Common Stock · Currency in USD · XNAS
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Company Info
SIC2834
Composite FIGIBBG0107FR3K9
CIK0001840904
IPOJun 18, 2021
Sectorpharmaceutical preparations
Highlights
Market Cap$1.38B
EPS-$1.12
P/E Ratio-5.63
Revenue$2.94M
Gross Profit$3.00M
Net Income-$244.39M
Employees54
WSO363,214,602
Phone49 89 2153 9035
Websitehttps://www.ataibeckley.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in AtaiBeckley Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
AtaiBeckley Inc. Common Stock (ATAI) has returned -9.55% so far this year and 215.83% over the past 12 months. Looking at the last ten years, ATAI has achieved an annualized return of -3.62%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
ATAI
1M4.99%
6M-28.49%
YTD-9.55%
1Y215.83%
5Y-29.00%
10Y-3.62%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of AtaiBeckley Inc. Common Stock (ATAI) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.26% | -2.94% | 1.14% | 6.31% | ||||||||
| 2025 | 13.14% | 16.22% | -21.39% | 10.29% | 55.03% | -12.75% | 55.30% | 14.50% | 18.88% | 10.61% | -33.50% | 7.07% |
| 2024 | 25.35% | 7.78% | 1.55% | 0.51% | -19.07% | -16.35% | 15.67% | -15.03% | -12.12% | -8.62% | 67.92% | -24.43% |
| 2023 | -34.32% | -5.08% | 7.10% | 0.26% | -5.79% | -3.91% | 19.43% | -26.44% | -15.69% | -4.65% | -16.80% | 30.56% |
| 2022 | -30.78% | 4.36% | -10.70% | -15.55% | -7.44% | -8.54% | 6.04% | 16.58% | -25.78% | -12.46% | 12.06% | -24.65% |
| 2021 | -11.90% | -16.26% | 3.67% | -13.86% | -0.61% | -24.90% | -30.76% | |||||
| 2019 | 18.68% | 4.59% | -13.73% | 86.14% | -2.93% | 50.00% | 3.30% | -29.47% | -12.37% | 14.37% | ||
| 2018 | 7.53% | 6.80% | -0.38% | 0.00% | 3.34% | -20.49% | 9.09% | -51.78% | -52.27% | 6.67% | -2.68% | -17.86% |
| 2017 | -20.21% | 26.93% | -0.78% | -2.93% | -3.01% | 25.28% | 5.26% | -0.85% | 4.30% | -2.05% | 9.13% | -7.60% |
| 2016 | 7.18% | -11.29% | -6.12% | -17.79% | 13.68% | -10.53% | -11.71% | 7.65% | 0.41% |
Performance Indicators
The charts below present risk-adjusted performance metrics for AtaiBeckley Inc. Common Stock (ATAI) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ATAI compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current AtaiBeckley Inc. Common Stock volatility is 4.68%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Liabilities And Equity (USD) | 159.39M | 293.48M | 305.44M | 414.17M |
| Temporary Equity (USD) | - | - | - | - |
| Equity Attributable To Parent (USD) | 116.30M | 242.96M | 260.74M | 376.91M |
| Equity Attributable To Noncontrolling Interest (USD) | 257.00K | 1.35M | 5.03M | 9.05M |
| Equity (USD) | 116.55M | 244.32M | 265.77M | 385.96M |
| Redeemable Noncontrolling Interest (USD) | - | - | - | - |
| Other Non-current Liabilities (USD) | 3.75M | 14.00M | 5.08M | - |
| Long-term Debt (USD) | 14.13M | 15.05M | 14.70M | - |
| Noncurrent Liabilities (USD) | 17.88M | 29.04M | 19.78M | 7.27M |
| Other Current Liabilities (USD) | 22.34M | 15.53M | 17.50M | 14.93M |
| Accounts Payable (USD) | 2.62M | 4.59M | 2.40M | 6.00M |
| Current Liabilities (USD) | 24.95M | 20.12M | 19.90M | 20.94M |
| Liabilities (USD) | 42.83M | 49.16M | 39.68M | 28.21M |
| Other Non-current Assets (USD) | 73.48M | 106.91M | 17.37M | 38.94M |
| Intangible Assets (USD) | 3.25M | - | - | - |
| Fixed Assets (USD) | 2.54M | 981.00K | 928.00K | 149.00K |
| Noncurrent Assets (USD) | 79.26M | 107.89M | 18.30M | 39.08M |
| Current Assets (USD) | 80.13M | 185.59M | 287.15M | 375.08M |
| Assets (USD) | 159.39M | 293.48M | 305.44M | 414.17M |
News and Insights
AtaiBeckley announced Q4 2025 financial results with $220.7M in cash runway through early 2029. The company received FDA approval to advance BPL-003 (mebufotenin benzoate nasal spray) into Phase 3 trials for treatment-resistant depression, with initiation planned for Q2 2026. EMP-01 (oral R-MDMA) met primary safety objectives in a Phase 2a social anxiety disorder trial with clinically meaningful efficacy improvements. VLS-01 Phase 2 data is anticipated in H2 2026.
Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.
AtaiBeckley presented clinical and preclinical data at the 64th Annual ACNP Meeting in Nassau, Bahamas. The company's Phase 2b study of BPL-003 (mebufotenin benzoate) nasal spray for treatment-resistant depression showed significant rapid and sustained antidepressant effects at 8mg and 12mg doses compared to control, with good tolerability. The presentation was selected for the prestigious Hot Topics Session. Additionally, preclinical data on 5-MeO-DMT's pharmacology and potential neuroplasticity effects were presented.
AtaiBeckley Inc (NASDAQ: ATAI), formed from the merger of atai Life Sciences and Beckley Psytech, announced its 2026 outlook ahead of the J.P. Morgan Healthcare Conference. The company reported positive Phase 2b data for BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, with Phase 3 trials expected in Q2 2026. Additional milestones include Phase 2 data for VLS-01 (DMT buccal film) in H2 2026 and EMP-01 (oral R-MDMA) for social anxiety disorder in Q1 2026. The company completed its redomiciliation to the United States in December 2025 and was added to the NASDAQ Biotechnology Index.
Atai Life Sciences received FDA Breakthrough Therapy designation for BPL-003, a nasal spray targeting treatment-resistant depression. The company also raised approximately $130 million through a stock offering to advance its clinical programs.
atai Life Sciences plans to raise approximately $130 million through a public offering of 23,725,000 common shares at $5.48 per share, with proceeds intended to advance clinical development of product candidates and support corporate operations.
atai Life Sciences received a multi-year, milestone-driven grant from NIDA to develop novel non-hallucinogenic 5-HT2A/2C receptor agonists for treating opioid use disorder, focusing on innovative drug discovery approaches.
Atai Life Sciences reported Q2 2025 financial results with mixed performance, including revenue of $0.72 million, reduced net loss of $27.7 million, and continued progress in mental health treatment drug development, with a strategic combination with Beckley Psytech planned.
atai Life Sciences and Beckley Psytech reported successful Phase 2b clinical trial results for BPL-003, a potential treatment for treatment-resistant depression, demonstrating rapid and durable antidepressant effects with a single intranasal dose and minimal side effects.